Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SMVD - Break did occur at 1.50 with a symmetrical triangle in a uptrend and the magic box!
Refer to previous reply from Gok
Hey Cats,
Got a question for you, if you don't mind.
I see you posted some bottom picks on the Seasonality & Seasonal Penny board, just wondering what you look for in bottom plays? If its a secret I understand!
Thanks
XDSL - posted about this company during the head fake breakout early October. Just wanted to show how important it is to sell when support cannot hold! Its a lesson I've learned the hard way on other plays. But its gonna make me a better trader lol!
Fat finger - closed at .16
Form 8-K for MPHASE TECHNOLOGIES INC
Reason for fall
17-Nov-2005
Other Events
Item 8.01 - Other Events
mPhase was advised in April 2002 that following an investigation by the staff of the Securities and Exchange Commission, the staff intended to recommend that the Commission file a civil injunctive action against Packetport.com, Inc. (Packetport) and its Officer's and Directors. Such recommendation related to alleged civil violations by Packetport and such Officers and Directors of various sections of the Federal Securities Laws. The staff has alleged civil violations of Sections 5 and 17(a) of the Securities Act of 1933 and Sections 10(b) and 13(d) of the Securities Exchanges Act of 1934. As noted in other public filings of mPhase, the CEO and COO of mPhase also serve as Directors and Officers of Packetport. At that time these persons advised mPhase that they deny any violation of law on their part and intend to vigorously contest such recommendation or action, if any.
On November 15, 2005, the Commission filed a civil enforcement action against 6 individuals and 4 companies as a result of its investigation in federal district court in the State of Connecticut alleging various violations of the Securities Act of 1933 including Sections 5, Section 17(a) and the Securities Exchange Act of 1934 including Sections 10b, Rule 10b-5, Sections, 12,Section 13, Section 16 in connection with the purchase and sale of stock of packetport.com in the period on or about December 14, 1999 into February of 2000. The defendants include the CEO and COO of mPhase as well as Microphase Corporation, a privately held Connecticut corporation, that shares common management with mPhase. mPhase is not named as a party in the enforcement action. The CEO and COO of mPhase and Microphase Corporation deny any violation of the law by each or any of them and intend to vigorously contest all charges set forth in such enforcement action by the Commission.
Thank you for the greetings!
I haven't ventured into FOREX, update me on how your experiment goes, goodluck!
So whats the overall consensus on the Frankfurt Exchange, I'm see alot of support for Canadian jr's over there!
Thanks Cat, I'll start watching that one!
GMX.TO - ever since the Frankfurt listing is company has been on a tear!
Chart on previous reply
Thanks Acura, its an OTC stock so it needs careful attention.
Thanks for the board, love blue skies! lol
Do you trade the more expensive stocks?
Friday's Trading
CMED 8.01%
PMTI 0.27%
CLZR 5.21%
STXS 9.76%
STJ 1.37%
ZOLL (0.84%)
NMTI 2.13%
Hoovers link to Suntech
http://www.hoovers.com/suntech-power/--ID__142982--/free-co-factsheet.xhtml
excellent advice indeed Ken! Gotta nail that one as well! lol
Suntech Power
http://www.suntech-power.com/en/index.asp
Chinese Solar-Power Co. Suntech Power Files for U.S. Initial Public Offering of Up to $300M
November 2, 2005 - 12:39:17
WASHINGTON (AP) - A Chinese manufacturer of solar cells, Suntech Power Holdings Co., has registered for a U.S. initial public offering of up to $300 million, according to a filing Tuesday with the Securities and Exchange Commission.
The company said it plans to list its American Depositary Receipts on the New York Stock Exchange under the symbol "STP."
The company said it intends to use about $100 million of the net proceeds for raw materials, about $40 million to expand manufacturing lines, about $20 million to enhance research and development efforts, and the remaining for general corporate purposes and for potential acquisitions.
LVLT - completing the cup
Was sooner then I thought.
LVLT - this is where it gets interesting,
Cup virtually filled now
&r=4271
I'm not to sure I think handle: IH Admin [Matt] might be able to help you out? Or you can start another one !
BIOM - This is one of the first plays I did, when I was more of a holder, went up 97% on me, didn't know about TA and then learned the idea of support and sold for a 10% loss! I cut my losses which was a great move, would've been down 40%. Had some good news today, but still a far way off! BLP25 so far has had good results, don't see it holding this level. But we will see.
BLP25 Liposome Vaccine phase 2 study interim results indicate no safety concerns with reformulated vaccine
Thursday November 17, 6:00 am ET
EDMONTON, Nov. 17 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced the interim results of a phase 2 non-small cell lung cancer (NSCLC) single-arm, multi-centre, open label study of BLP25 Liposome Vaccine (L-BLP25) showing that the new formulation of the vaccine is not different from the previous formulation from a safety perspective. The reformulated vaccine incorporated manufacturing changes intended to secure the future commercial supply of the vaccine.
Though not a head-to-head comparison, the phase 2 trial compared the new formulation of L-BLP25 to the formulation used in the phase 2b trial, which was completed in 2004. A comparison of baseline and post-four vaccination laboratory tests for each trial, and between trials was conducted. For the majority of patients in both trials, the laboratory results were within the normal range for both time points. Also examined, for the same time frame, were adverse events, and injection site reactions. Although the two trials have slightly different patient populations and different sample sizes, based on the information reviewed, there is no clinical rationale to indicate that the two vaccine formulations are different from a safety perspective. The new formulation incorporated manufacturing changes intended to secure the future commercial supply of the vaccine.
In October, Biomira and Merck KGaA of Darmstadt, Germany announced that follow-up of patients enrolled in the phase 2b trial had determined a median survival for the vaccinated subset of Stage IIIB locoregional patients of 30.6 months compared to 13.3 months observed for the same stage patients who did not receive the vaccine, a difference of 17.3 months.
Tests to resolve a contract manufacturing stability issue are ongoing, with results expected in the first quarter of 2006.
The Companies
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).
Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,600 employees in 54 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73 per cent interest and free shareholders own the remaining 27 per cent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. Merck KGaA has built a strategic oncology portfolio by developing and in-licensing product candidates in four areas -- monoclonal antibodies, therapeutic vaccines, immunocytokines and angiogenesis inhibitors.
EMD Pharmaceuticals Inc., the U.S. affiliate of Merck KGaA, is a fully integrated pharmaceutical company with an initial emphasis on launching new products in oncology. Located in Durham, N.C., EMD focuses on meeting patient and physician needs with pioneering pharmaceutical products and services.
- - -
Hey GOK -
you made your new board only for paying customers! We both have to pay now! lol
I should've included this as well
Medical Instruments & Supplies
http://biz.yahoo.com/ic/520.html
In our Over $5 Project as well
Over $5 Project
Areas of concern
ONCY - slightly under $5 should be our stop
MPWR - major sell off yesterday, needs more attention
PWEI - stop at $15.00 to protect profits, need to be more aggresive in taking profits! Lesson Learned!
IFO - having trouble holding 10.00
Interesting movement:
CPTS - nice movement for the week so far
NETL - first time over $25.00, we'll see if it can hold
CMED - new 52 week high
I'll provide an update on all stocks we are watching this weekend. I would appreciate any feedback, constructive criticism to make me a better trader! Thanks
Thanks Castle, I go over the list everyday! Thanks
Been following BBW - like Build A Bear concept, there stores are so much fun! And its been having a nice run so far. Others that have got my attention are QSII, JOSB, RMD, CUTR, MCRS, and PMTI. I must say its fun getting away from penny's at times! Less stress so far!
Makes perfect sense, your magic box, fairy square and knights crossing promote discpline! And discpline is the key to sustained profits and waiting for the comfirmation is vital! Nice job!
Please, I don't want to be blamed, lol!
New OSC boss renews call for single regulator, urges hedge fund transparency
From the Canadian Press
11/17/05 3:27:00 PM
TORONTO (CP) - The new chairman of the Ontario Securities Commission has renewed his predecessor's call for a single Canadian regulator of financial markets.
David Wilson also said Thursday in his first public speech as head of Canada's biggest securities commission that the OSC will be pressing hedge funds to provide more information about their workings and will be seeking tougher penalties against thieves, fraudsters and insider-trading violators.
"We need a common securities regulator in Canada to improve both the efficiency and attractiveness of our capital market," Wilson, who took over Nov. 1 from David Brown, told an OSC conference.
Reprising a well-worn theme, he added: "Any change must be pursued and implemented in a co-operative manner, taking into account regional needs."
The idea of a national regulator, supported by the Ontario and federal governments as well as the OSC, has for years run up against objections from Quebec, British Columbia and Alberta, which fear domination by Toronto.
In the hedge fund sector, Wilson said recent scandals, notably the collapse of Portus Asset Management of Toronto, have highlighted the need for greater transparency.
He noted that Canadian hedge funds, extending beyond their former clientele of wealthy investors who can take care of themselves, have exploded in value from $4 billion to over $30 billion in five years, and because of their high-velocity trading may account for nearly one-third of market activity.
They provide liquidity and drive efficiency but "we must consider measures designed to ensure that hedge fund managers provide fair, full, accurate and timely information to their investing clients," Wilson said.
"And we must consider the steps we should take to improve transparency regarding fees and risks within the often complex provisions of their financial maze."
Wilson, 60, formerly CEO of Scotia Capital, also noted that the OSC faces a decision on whether to impose a requirement on Canadian corporations paralleling Section 404 of the U.S. Sarbanes-Oxley Act, which forces companies to implement and document internal controls on their financial reporting.
Canadian enterprises with securities listed on U.S. markets already must comply with SOX 404, but "about 1,100 Canadian companies, with market cap of half a trillion dollars, are awaiting our decision," Wilson observed.
He gave no indication of what the commission will decide, but noted that for many companies SOX 404 "could constitute a huge burden, involving layers of costs," and if these costs outweigh the benefits for investor confidence, "then we will have to find a unique Canadian approach."
On the enforcement front, "we must continue to close the historic gap between securities regulation and criminal law enforcement," Wilson said.
And penalties must be toughened so they are regarded as a real risk - not merely "an opportunity to persuade violators to reform their ways after they have been caught."
Last week, the stocks regulator charged two men with insider trading of shares in Agnico-Eagle Mines Ltd., a Toronto-based gold miner.
Barry Landen, who was the miner's vice-president of corporate affairs until last December, was charged with one count of insider trading and one count of tipping. Stephen Diamond, a chartered accountant, was charged with one count of insider trading.
Those charges come just weeks after the trial of former Toronto investment banker Andrew Rankin wrapped up, ending with a six-month jail sentence for Rankin after Canada's first tipping conviction. Rankin, who was cleared of 10 insider trading charges, was found guilty of sharing insider stock tips with a friend prior to 10 major Canadian business deals.
Observers of that case speculated that successful tipping charges and the jail sentence would spur the OSC to take on more tipping and insider trading cases, which are notoriously difficult to prove.
© The Canadian Press, 2005
Interesting movement from Medical Equipment makers
Castle helped me figure this out by posting the hot growth list, Thanks Castle.
Yahoo Industry Center - Medical Appliances & Equipment
http://biz.yahoo.com/ic/521.html
On our Over $5 project
>
>
>
Beaten for a reason
>
>
VSTH - 11/04/05 Scan
The last two trading days were telling us of the move
Resistance @ 1.55
>
Can I request my first chart SA?
STTK - caught my eye a couple of days ago
STTK - 51 cents 3yr high, deserves to be watched
>
>
STTK - been following this; nice gains so far and broke out
>
>
No I didn't but I've got you earmarked now !
Nice follow up on EZEM today! Nice job.
Some scans that we've looked at:
WDPT - 11/13/05 Scan
These are the ones that stick out so far, ACUR is retreating but did produce some nice gains. Others haven't done well or support was broken
>
>
EGSR - 11/04/05 Scan - banging its head against .70
>
>
BTYH - 11/15/05 Scan
Holding so far, some more volume would be nice
>
>
STTK - 11/16/05 - Scan
nice gains so far -GOK approvable rating- Last Gok approvable was EGSR! Always a good vote of confidence, keep it up JP
>
>
Slow and steady, $5.00 test - 11/03/05 Scan
>
>
CDN Stocks: Nov.17th
>
>
>
>
>
>
>
>
You do pick some sweet set ups!
My Under $5.00 from yesterday: ACUR had an impressive day, but sold off towards the end of the day
STTK - has had impressive volume but up only 2 cents.
GOK - SOIGF
What a bounce of 1.57, not for the faint at heart OTC or Pinks.
Hello til1then,
Thats a nice break til1then, thanks for letting me know about this. Some higher volume would be nice. Thanks
Gok's at Seasonal Penny Board Template
>
shave his head! lol
ECPN Sweet call Gok! You do have the magic! Last sale 1.60
GTE - Sanswire flight news test ... and PPS goes up, as expected
TRE - got that break you were looking for Gok.
LMIA Nov.11th Scan & IFO Nov.10 Scan still showing strength
Both charts below
>
Thanks Gok, seems CPST had the insane Cramer effect. Lets see if it can hold now.